Curcumin for Clonal Cytopenia and Related Conditions

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Recruiting Phase 2 Interventional Study
Clonal Cytopenia of Undetermined Significance Essential Thrombocythemia Myelodysplastic Syndrome Myelofibrosis Polycythemia Vera
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
30 (estimated)
Sponsor
University of Southern California · Other
Who this trial is looking for

This trial is looking for adults with specific blood disorders like clonal cytopenia and low-risk myelodysplastic syndrome. Participants will take a curcumin supplement to see if it helps reduce inflammation and improve symptoms.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am at least 18 years old.
  • I understand and am willing to sign consent forms.
  • I have been diagnosed with polycythemia vera, essential thrombocytosis, or myelofibrosis.
  • I have at least one measurable symptom that is severe.
  • I have a diagnosis of clonal cytopenia or low-risk myelodysplastic syndrome.
  • I have symptoms of fatigue with a specific score.

You may not be able to join if

  • I have taken curcumin supplements in the past.
  • I cannot understand or follow instructions.
  • I am receiving treatment for another cancer.
  • I have intermediate or high-risk myelodysplastic syndrome.
  • I am pregnant or nursing.
  • I am taking steroids or other anti-inflammatory medications.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age \>= 18 * Eastern Cooperative Oncology Group (ECOG) =\< 2 * Ability to understand and willingness to sign a written informed consent * Diagnosis of polycythemia vera (PV), essential thrombocytosis (ET) or myelofibrosis (MF) per World Health Organization (WHO) 2016 diagnosti…
Contacts

Christine Duran

323-865-0371

duran_c@med.usc.edu

CONTACT